34 related articles for article (PubMed ID: 15481766)
1. The effect of caffeine and albuterol on body composition and metabolic rate.
Liu AG; Arceneaux KP; Chu JT; Jacob G; Schreiber AL; Tipton RC; Yu Y; Johnson WD; Greenway FL; Primeaux SD
Obesity (Silver Spring); 2015 Sep; 23(9):1830-5. PubMed ID: 26239482
[TBL] [Abstract][Full Text] [Related]
2. Individuals with hypertension have lower plasma volume regardless of weight status.
Spitz RW; Loprinzi PD; Loenneke JP
J Hum Hypertens; 2023 Jun; 37(6):491-495. PubMed ID: 35568725
[TBL] [Abstract][Full Text] [Related]
3. Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Yoo HJ; Yoon HY; Yee J; Gwak HS
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832979
[TBL] [Abstract][Full Text] [Related]
4. Muscle uncoupling protein 3 expression is unchanged by chronic ephedrine/caffeine treatment: results of a double blind, randomised clinical trial in morbidly obese females.
Bracale R; Petroni ML; Davinelli S; Bracale U; Scapagnini G; Carruba MO; Nisoli E
PLoS One; 2014; 9(6):e98244. PubMed ID: 24905629
[TBL] [Abstract][Full Text] [Related]
5. The Role of Beta-Blockers in the Treatment of Hypertension.
Cruickshank JM
Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
[TBL] [Abstract][Full Text] [Related]
6. [Is Letigen contraindicated in hypertension? A double-blind, placebo controlled multipractice study of Letigen administered to normotensive and adequately treated patients with hypersensitivity].
Svendsen TL; Ingerslev J; Mørk A
Ugeskr Laeger; 1998 Jun; 160(27):4073-5. PubMed ID: 9659838
[TBL] [Abstract][Full Text] [Related]
7. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial.
Astrup A; Breum L; Toubro S; Hein P; Quaade F
Int J Obes Relat Metab Disord; 1992 Apr; 16(4):269-77. PubMed ID: 1318281
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
[TBL] [Abstract][Full Text] [Related]
9. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice.
Breum L; Pedersen JK; Ahlstrøm F; Frimodt-Møller J
Int J Obes Relat Metab Disord; 1994 Feb; 18(2):99-103. PubMed ID: 8148931
[TBL] [Abstract][Full Text] [Related]
10. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
[TBL] [Abstract][Full Text] [Related]
11. Is an ephedrine caffeine treatment contraindicated in hypertension?
Ingerslev J; Svendsen TL; Mørk A
Int J Obes Relat Metab Disord; 1997 Aug; 21(8):666-73. PubMed ID: 15481766
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
